CORRECTION

Correction to: Proton pump inhibitor monotherapy is effective to attenuate dyspepsia symptoms associated with gastroesophageal reflux disease: a multicenter prospective observational study

Kimio Isshi^{1,2} · Nobuyuki Matsuhashi³ · Takashi Joh⁴ · Kazuhide Higuchi⁵ · Katsuhiko Iwakiri⁶ · Takeshi Kamiya⁷ · Noriaki Manabe⁸ · Maiko Ogawa⁹ · Seiji Arihiro⁹ · Ken Haruma¹⁰ · Koji Nakada¹¹

Published online: 11 March 2019
© Japanese Society of Gastroenterology 2019

Correction to: J Gastroenterol

<https://doi.org/10.1007/s00535-019-01546-0>

In the original publication of this article, Tables 2, 3, 4, 5 and 6 were published incorrectly. The correct tables are given in this correction.

The original article can be found online at <https://doi.org/10.1007/s00535-019-01546-0>.

✉ Kimio Isshi
isshi-ki@jikei.ac.jp

¹ Isshi Gastro-Intestinal Clinic, 2-15-21, Shinozaki-Cho, Edogawa-ku, Tokyo 133-0061, Japan

² Department of Endoscopy, Jikei University School of Medicine, 3-15-8 Nishishinbashi, Minato-Ku, Tokyo 105-8461, Japan

³ Department of Gastroenterology, NTT Medical Center Tokyo, 5-9-22, Higashi-Gotanda, Shinagawa-Ku, Tokyo 105-8461, Japan

⁴ Gamagori City Hospital, 1-1 Mukaida, Hirata—Cho, Gamagori-City, Aichi 443-8501, Japan

⁵ Second Department of Internal Medicine, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka 569-8686, Japan

⁶ Department of Gastroenterology, Nippon Medical School Graduate School of Medicine, 1-1-5, Sendagi, Bunkyo-Ku, Tokyo 133-8603, Japan

⁷ Department of Medical Innovation, Nagoya City University Graduate School Medical Sciences, 1, Kawasumi, Mizuho-Cho, Mizuho-Ku, Nagoya 467-8601, Japan

⁸ Division of Endoscopy and Ultrasonography, Department of Laboratory Medicine, Kawasaki Medical School General Medical Center, 2-6-1, Nakayamashita, Kita-Ku, Okayama-City, Okayama 700-8505, Japan

⁹ Division of Gastroenterology and Hepatology, Department of Internal Medicine, Katsushika Medical Center Jikei University School of Medicine, 6-41-2, Aoto, Katsushika-Ku, Tokyo 125-8506, Japan

¹⁰ Department of General Internal Medicine 2, Kawasaki Medical School Kawasaki Hospital, 577, Matsushima, Kurashiki, Okayama 701-0192, Japan

¹¹ Department of Laboratory Medicine, The Jikei University Daisan Hospital, 4-11-1, Izumihon-Cho, Komae-City, Tokyo 201-8601, Japan

Table 2 Patients' characteristics

	Total (<i>n</i> = 233)	GERD-SS $\leq$ 2.5 mild symptom (<i>n</i> = 40)	GERD-SS 3.0–4.5 moderate symptom (<i>n</i> = 151)	GERD-SS $\geq$ 5.0 severe symptom (<i>n</i> = 42)	<i>p</i> - value	Mild vs moderate <i>p</i> -value ^c	Moderate vs severe <i>p</i> -value ^c	Mild vs severe <i>p</i> -value ^c
Age (year)*	56.5 $\pm$ 14.1	56.7 $\pm$ 15.5	56.9 $\pm$ 13.0	54.7 $\pm$ 16.4	0.675 ^a	0.996	0.652	0.804
BMI (kg/m ²)*	23.7 $\pm$ 3.7	22.3 $\pm$ 3.3	23.8 $\pm$ 3.5	24.7 $\pm$ 4.5	0.014 ^a	0.054	0.395	0.012
Gender: <i>n</i> (%)					0.007 ^b			
Male	136 (58)	29 (73)	87 (58)	20 (48)				
Female	97 (42)	11 (28)	64 (42)	22 (52)				
Endoscopic finding: <i>n</i> (%)								
NERD/ERD					0.725 ^b			
NERD	94 (41)	18 (45)	58 (39)	18 (43)				
ERD	138 (59)	22 (55)	92 (61)	24 (57)				
LA classification					0.916 ^b			
Grade N	58 (25)	12 (30)	34 (23)	12 (29)				
Grade M	36 (16)	6 (15)	24 (16)	6 (14)				
Grade A	71 (31)	12 (30)	45 (30)	14 (33)				
Grade B	49 (21)	7 (18)	36 (24)	6 (14)				
Grade C	16 (7)	3 (8)	9 (6)	4 (10)				
Grade D	2 (1)	0 (0)	2 (1)	0 (0)				

GERD gastroesophageal reflux disease, SS symptom subscale, BMI body mass index, NERD non-erosive reflux disease, ERD erosive reflux disease, LA Los Angeles

*Data are presented as mean $\pm$ SD

^aanalysis of variance (ANOVA)

^bChi-square test

^cTukey test

Table 3 Comparison of the GERD and FD symptom scores at baseline among the groups divided by the severity of GERD-SS before PPI therapy

	Total (<i>n</i> = 233)	GERD-SS $\leq$ 2.5 mild symptom (<i>n</i> = 40)	GERD-SS 3.0–4.5 moderate symptom (<i>n</i> = 151)	GERD-SS $\geq$ 5.0 severe symptom (<i>n</i> = 42)	<i>p</i> -value ^a	Mild vs moderate		Moderate vs severe		Mild vs severe	
						<i>p</i> -value ^b	Cohen's <i>d</i> ^c	<i>p</i> -value ^b	Cohen's <i>d</i> ^c	<i>p</i> -value ^b	Cohen's <i>d</i> ^c
GERD-SS*	3.7 $\pm$ 1.1	2.1 $\pm$ 0.4	3.6 $\pm$ 0.5	5.5 $\pm$ 0.6	< 0.001	< 0.001	2.88	< 0.001 ^b	3.42	< 0.001 ^b	6.54
FD-SS*	3.3 $\pm$ 0.9	2.6 $\pm$ 0.6	3.2 $\pm$ 0.7	4.3 $\pm$ 1.1	< 0.001	< 0.001	0.79	< 0.001 ^b	1.43	< 0.001 ^b	1.99
FD-EPS-Sx*	3.6 $\pm$ 1.2	2.6 $\pm$ 1.2	3.5 $\pm$ 0.9	4.8 $\pm$ 1.3	< 0.001	< 0.001	0.91	< 0.001 ^b	1.28	< 0.001 ^b	1.81
FD-PDS-SS*	3.0 $\pm$ 1.2	2.7 $\pm$ 1.0	2.9 $\pm$ 1.0	3.9 $\pm$ 1.3	< 0.001	0.521	0.21	< 0.001 ^b	0.91	< 0.001 ^b	1.05

SS symptom subscale, EPS epigastric pain syndrome, Sx symptom, PDS postprandial distress syndrome

*Data are presented as mean $\pm$ SD

^aAnalysis of variance (ANOVA)

^bTukey test

^cInterpretation of effect size (Cohen's *d*); $\geq$ 0.2:small, $\geq$ 0.5:medium, $\geq$ 0.8:large

Table 4 Comparison of the GERD and FD symptom scores between at before and at after 4 weeks of PPI therapy in the groups divided by the severity of GERD-SS at baseline

	Total cases (<i>n</i> = 233)				GERD-SS ≤ 2.5 (<i>n</i> = 40) mild symptom				GERD-SS 3.0–4.5 (<i>n</i> = 151) moderate symptom				GERD-SS ≥ 5.0 (<i>n</i> = 42) severe symptom			
	After Tx		<i>p</i> -value ^a	Cohen's <i>d</i> ^b	After Tx		<i>p</i> -value ^a	Cohen's <i>d</i> ^b	After Tx		<i>p</i> -value ^a	Cohen's <i>d</i> ^b	After Tx		<i>p</i> -value ^a	Cohen's <i>d</i> ^b
	Before Tx				Before Tx				Before Tx				Before Tx			
GERD-SS*	3.7 ± 1.1	2.0 ± 1.1	< 0.001	1.47	2.1 ± 0.4	1.8 ± 1.0	0.030	0.58	3.6 ± 0.5	2.0 ± 1.0	< 0.001	1.91	5.5 ± 0.6	2.5 ± 1.4	< 0.001	3.35
FD-SS*	3.3 ± 0.9	2.1 ± 0.1	< 0.001	1.24	2.6 ± 0.6	2.2 ± 1.0	0.018	0.64	3.2 ± 0.7	2.0 ± 0.9	< 0.001	1.50	4.3 ± 1.1	2.5 ± 1.2	< 0.001	1.69
FD-EPS-Sx*	3.6 ± 1.2	2.1 ± 1.2	< 0.001	1.29	2.6 ± 1.2	1.9 ± 1.2	0.008	0.59	3.5 ± 0.9	2.0 ± 1.1	< 0.001	1.52	4.8 ± 1.3	2.5 ± 1.4	< 0.001	1.79
FD-PDS-SS*	3.0 ± 1.2	2.1 ± 1.0	< 0.001	0.82	2.7 ± 1.0	2.4 ± 1.1	0.273	0.25	2.9 ± 1.0	2.0 ± 0.9	< 0.001	0.95	3.9 ± 1.3	2.5 ± 1.2	< 0.001	1.06

Tx treatment

*Data are presented as mean $\pm$ SD^apaired *t*-test^bInterpretation of effect size (Cohen's *d*): ≥ 0.2 : small, ≥ 0.5 : medium, ≥ 0.8 : large**Table 5** Comparison of the GERD and FD symptom score changes by 4 weeks of PPI therapy among the groups divided by the severity of GERD-SS at baseline

	GERD-SS ≤ 2.5 mild symptom ($n = 40$)				GERD-SS 3.0–4.5 moderate symptom ($n = 151$)				GERD-SS ≥ 5.0 severe symptom ($n = 42$)			
	Total ($n = 233$)		p-value ^a		Mild vs moderate		Moderate vs severe		Mild vs severe		Cohen's <i>d</i> ^c	
	Before Tx	After Tx	Before Tx	After Tx	Before Tx	After Tx	Before Tx	After Tx	Before Tx	After Tx	Before Tx	After Tx
Δ GERD-SS*	– 1.7 $\pm$ 1.4	– 0.4 $\pm$ 1.0	– 0.4 $\pm$ 1.0	– 1.6 $\pm$ 1.1	– 1.6 $\pm$ 1.1	– 3.0 $\pm$ 1.5	< 0.001	1.14	< 0.001	1.14	< 0.001	2.06
Δ FD-SS*	– 1.2 $\pm$ 1.2	– 0.5 $\pm$ 1.2	– 0.5 $\pm$ 1.2	– 1.2 $\pm$ 1.0	– 1.2 $\pm$ 1.0	– 1.9 $\pm$ 1.5	< 0.001	0.73	< 0.001	0.59	< 0.001	1.04
Δ FD-EPS-Sx*	– 1.5 $\pm$ 1.5	– 0.7 $\pm$ 1.6	– 0.7 $\pm$ 1.6	– 1.5 $\pm$ 1.3	– 1.5 $\pm$ 1.3	– 2.3 $\pm$ 2.0	< 0.001	0.63	0.0043	0.56	< 0.001	0.93
Δ FD-PDS-SS*	– 0.9 $\pm$ 1.2	– 0.3 $\pm$ 1.4	– 0.3 $\pm$ 1.4	– 0.9 $\pm$ 1.0	– 0.9 $\pm$ 1.0	– 1.4 $\pm$ 1.3	< 0.001	0.58	0.005	0.45	< 0.001	0.84

 Δ change in symptom score (symptom score at 4 weeks of PPI therapy—symptom score at baseline)*Data are presented as mean $\pm$ SD^aanalysis of variance (ANOVA)^bTukey test^cInterpretation of effect size (Cohen's *d*): ≥ 0.2 : small, ≥ 0.5 : medium, ≥ 0.8 : large

Table 6 Effect of factors on FD–SS score changes by 4 weeks of PPI therapy ($n = 233$)

Multiple regression analysis		
Factor	β^*	p -value
Endoscopic findings (NERD)	0.090	0.1355
GERD-SS	– 0.411	< 0.001
R^{2**}	0.173	< 0.001
Interpretation of effect size	β	R^2
None or very small	< 0.100	< 0.020
Small	$\geq$ 0.100	$\geq$ 0.020
Medium	$\geq$ 0.300	$\geq$ 0.130
Large	$\geq$ 0.500	$\geq$ 0.260

* β standardized regression coefficient

** R^2 : coefficient of determination